AMRI Appoints New General Manager of Large Scale Manufacturing

AMRI (NASDAQ: AMRI) has named Richard A. Saffee as general manager of large scale manufacturing reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing.

Mr. Saffee will assume responsibility for all large scale manufacturing operations in Rensselaer, New York including oversight for engineering, manufacturing and materials management.

Mr. Saffee brings over 23 years of industrial and leadership experience in the chemical manufacturing of bulk Active Pharmaceutical Ingredients (API) in both human and animal health. Most recently, he led manufacturing activities for multiple US-based operations as site leader for Pfizer Global Manufacturing. Prior to that, he served as site leader for a Pfizer Global Human Health bulk API operation in Holland, Michigan previously owned by Parke-Davis. Prior to the Pfizer acquisition, Mr. Saffee held roles of increasing responsibility at Parke-Davis including director of chemical manufacturing and area production manager. He has extensive knowledge in the areas of chemical manufacturing, technology transfer, regulatory compliance and quality standards, purchasing and materials management, and managing global relationships. He is also trained in Lean Six Sigma techniques.

Mr. Saffee earned a master’s degree in business administration from Grand Valley State University in Allendale, Michigan and a bachelor’s of science degree in chemical engineering from the University of Michigan in Ann Arbor, Michigan.

AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen said, "It is with pleasure that we welcome Mr. Saffee to the AMRI manufacturing leadership team. We are confident that his considerable expertise in leading API manufacturing operations in the large pharmaceutical environment will benefit the performance of this facility. The addition of Mr. Saffee, along with several other recent initiatives in our large scale business, is part of a plan to further improve our operations and provide enhanced capabilities, results and value for our customers.”

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, delay or denial of approvals from the FDA, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission on March 17, 2008 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.